Could targeting metabolism treat blood clots in antiphospholipid syndrome? 

Targeting glycolysis can help lower neutrophil extracellular trap formation in antiphospholipid syndrome

5:00 AM

Author | Valerie Goodwin

blood vial blue yellow
Jacob Dwyer, Justine Ross, Michigan Medicine

Neutrophils are an important type of white blood cell that help your immune system fight infections.  

One of the many ways neutrophils help is by capturing germs in sticky, spider web-like structures called neutrophil extracellular traps, or NETs.

However, excessive formation of NETs is seen in many autoimmune diseases as a sign of exuberant inflammation.

In the autoimmune disease known as antiphospholipid syndrome, this inflammation causes blood clots, strokes and miscarriages. 

Antiphospholipid syndrome is usually treated with blood thinners that patients take for the rest of their lives. 

Unfortunately, blood thinning medicines don’t prevent future blood clots in all patients with the disease. 

Blood thinners also have important side effects to be aware of, such as major bleeding. 

Patients with antiphospholipid syndrome need better treatments, especially ones with fewer side effects. 

One promising approach is to target neutrophils and NETs. 

A research team at University of Michigan Health led by Ajay Tambralli, M.D., a clinical assistant professor in both adult and pediatric rheumatology, is investigating how metabolism – the process by which cells turn sugars, fats and proteins into energy – is used to make NETs. 

They’re also using this knowledge to develop treatments based on metabolism to lower the propensity of neutrophils to make NETs in APS. 

The team’s study found neutrophils from antiphospholipid syndrome  patients use a metabolic process called glycolysis more aggressively than neutrophils from healthy people. 

Glycolysis converts sugars into energy and generates by-products used for different purposes in the cell. 

The authors found that one such by-product called glucose-6-phosphate feeds into another metabolic process known as the pentose phosphate pathway. 

The pentose phosphate pathway then arms the neutrophils to make NETs. 

“When we disrupted either glycolysis or the pentose phosphate pathway, neutrophils made fewer NETs. Fewer NETs meant smaller blood clots in our model systems,” said Tambralli. 

Promisingly, they also found that this strategy didn’t increase bleeding. 

“These findings are an important step to better understanding how metabolism is altered in APS.” 

Armed with this knowledge, the research team has begun investigating the underlying causes of the metabolic alterations in antiphospholipid syndrome.

“We want to gain a clearer picture of what is driving the increase in glycolysis, which can then be harnessed to develop metabolism-focused treatments for APS,” said Tambralli. 

Though more research is needed, the goal is to bring such treatments to patients with antiphospholipid syndrome  and, potentially, other diseases where NETs cause blood clotting. 

“Part of the treatment regimen might be adjusting how someone eats, 'putting neutrophils on a diet,’ if you will. We have some ideas on this front that we will test in our next manuscript. The goal is to keep the neutrophils healthy for fighting infections but stopping the excessive NETs that lead to blood clots.” 

The hope is to make strategic treatment decisions to address the root causes of antiphospholipid syndrome  for each individual patient.

Additional authors: Alyssa Harbaugh, Somanathapura K. NaveenKumar, Christine E. Rysenga, Kaitlyn Sabb, Julia Hurley, Gautam Sule, Srilakshmi Yalavarthi, Shanea K. Estes, Claire K. Hoy, Tristin Smith, Cyrus Sarosh, Yu Zuo, and Jason S. Knight from the Division of Rheumatology, Department of Internal Medicine, University of Michigan, Megan D. Radyk and Costas A. Lyssiotis from the Department of Molecular and Integrative Physiology, University of Michigan,  Jacqueline A. Madison from the Division of Rheumatology, Department of Internal Medicine,  and the Division of Pediatric Rheumatology, Department of Pediatrics, University of Michigan,  Jordan K. Schaefer and Suman L. Sood from the Division of Hematology & Oncology, Department of Internal Medicine, University of Michigan,and Amr H. Sawalha from the Departments of Pediatrics, Medicine, and Immunology, and Lupus Center of Excellence, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Funding: This work was supported by a grant from the Rheumatology Research Foundation (AT) and by NIH/NHLBI R01HL134846 (JSK).

Paper cited: “Neutrophil glucose flux as a therapeutic target in antiphospholipid syndrome,” JCI. DOI: 10.1172/JCI169893 

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week by subscribing to Health Lab’s two newsletters, Health & Wellness and Research & Innovation. 

Sign up for the Health Lab Podcast: Add us on Spotify, Apple Podcasts or wherever you get you listen to your favorite shows. 


More Articles About:

Basic Science Basic Science and Laboratory Research metabolism Rheumatology
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

Jay Tambralli

Ajay Tambralli, MD

Clinical Assistant Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
1906 psychopathic hospital
News Release

Exploring the mind’s mysteries: 130 years of mental health care & innovation at U-M

When it opened in 1906 on Catherine Street near the University of Michigan’s main hospitals, the stately brick State Psychopathic Hospital meant something new in the world of mental health.
Perforin increases endosomal-mitochondrial contact sites in tumor cells. Left is without perforin; right has perforin.
Health Lab

Immune system protein is a cancer killer on its own, new study shows

New study finds perforin can kill cancer tumor cells even when major granzymes were missing.
Purple shaded illustration of doctor listening to heart of patient on a bed
Health Lab

The AI is listening: Implications of machine generated clinical notes on health care

Michigan Medicine experts argue that use of artificial intelligent scribes during health care visits should be more carefully examined .
scratching arm pink sweater in living room teal couch
Health Lab

A metabolic “switch” that could help reset scar-producing cells in scleroderma

Researchers at University of Michigan Health and collaborating institutions have identified a metabolic enzyme that may offer a fundamentally new way to attack one of the most difficult-to-treat features of systemic sclerosis, or scleroderma: progressive and potentially life threatening tissue scarring.
graphic of red green orange blue close up of inside of body and insides shaking
Health Lab

Pain, psychological factors and physical function closely linked in people with systemic sclerosis

For many people living with chronic conditions like systemic sclerosis, pain can be persistent, unpredictable, and difficult to manage leading to a strong impact on a patient’s mental health.